美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Galena Biopharma

0.2620

0.0000

成交量：- -

成交額：- -

市值：1,006.21萬

市盈率：-0.11

高：0.2620

開：0.2620

低：0.2620

收：0.2620

52周最高：2.41

52周最低：0.2568

股本：3,840.50萬

流通股本：937.02萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.2900

淨資產收益率：--

總資產收益率：--

市淨率：0.53

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Galena Biopharma

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.galenabiopharma.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Galena Biopharma, Inc.在美國特拉華州於2006年4月3日成立作為淘金製藥公司，並2006年11月28日更名為瑞克斯的製藥公司。2011年9月26日，公司把名稱改為格拉納生物製藥有限公司。格拉納是一家生物技術公司，致力於發現，開發和商業化創新療法來滿足使用有針對性的生物療法的主要醫療需求。格拉納是追求用肽為基礎的免疫療法產品的新的癌症治療學的發展，包括其主要的候選產品肽類（E75）用於治療乳腺癌和其他腫瘤。在低到中等HER2陽性乳腺癌患者不符合曲妥珠單抗里，肽類藥物是一種肽為基礎的免疫療法旨在降低乳腺癌的複發率。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/GALE/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GALE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GALE\",,,,,undefined,":{"symbol":"GALE","market":"US","secType":"STK","nameCN":"Galena Biopharma","latestPrice":0.262,"timestamp":1514581200000,"preClose":0.262,"halted":4,"volume":0,"delay":0,"floatShares":9370232,"shares":38405000,"eps":-2.29,"marketStatus":"退市","change":0,"latestTime":"10-16 15:20:11 EDT","open":0.262,"high":0.262,"low":0.262,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.29,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1760644800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.262,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GALE\",,,,,undefined,":{"symbol":"GALE","floatShares":9370232,"roa":"--","roe":"--","lyrEps":0,"shares":38405000,"dividePrice":0,"high":0.262,"amplitude":0,"preClose":0.262,"low":0.262,"week52Low":0.2568,"pbRate":"0.53","week52High":2.41,"institutionHeld":0,"latestPrice":0.262,"eps":-2.29,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.29,"open":0.262},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GALE\",params:#limit:5,,,undefined,":[{"date":"2018-01-02","symbol":"GALE","type":"split","dateTimestamp":1514869200000,"forFactor":30,"toFactor":1},{"date":"2018-01-02","symbol":"GALE","newSymbol":"SLS","type":"symbolChange","dateTimestamp":1514869200000},{"market":"US","date":"2017-11-09","symbol":"GALE","fiscalQuarterEnding":"2017/09","expectedEps":-0.15,"name":null,"time":"","type":"earning","dateTimestamp":1510203600000,"reportTimeType":"","actualEps":-0.15},{"market":"US","date":"2017-08-14","symbol":"GALE","fiscalQuarterEnding":"2017/06","expectedEps":-0.15,"name":null,"time":"盤後","type":"earning","dateTimestamp":1502683200000,"reportTimeType":"post","actualEps":-0.16},{"market":"US","date":"2017-05-10","symbol":"GALE","fiscalQuarterEnding":"2017/03","expectedEps":-0.22,"name":null,"time":"","type":"earning","dateTimestamp":1494388800000,"reportTimeType":"","actualEps":-0.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GALE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GALE\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.galenabiopharma.com","stockEarnings":[{"period":"1week","weight":-0.9667},{"period":"1month","weight":-0.9667},{"period":"3month","weight":-0.9667},{"period":"6month","weight":-0.9667},{"period":"1year","weight":-0.9667},{"period":"ytd","weight":-0.9667}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.0064},{"period":"3month","weight":0.0591},{"period":"6month","weight":0.2636},{"period":"1year","weight":0.1473},{"period":"ytd","weight":0.1349}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Galena Biopharma, Inc.在美國特拉華州於2006年4月3日成立作為淘金製藥公司，並2006年11月28日更名為瑞克斯的製藥公司。2011年9月26日，公司把名稱改為格拉納生物製藥有限公司。格拉納是一家生物技術公司，致力於發現，開發和商業化創新療法來滿足使用有針對性的生物療法的主要醫療需求。格拉納是追求用肽為基礎的免疫療法產品的新的癌症治療學的發展，包括其主要的候選產品肽類（E75）用於治療乳腺癌和其他腫瘤。在低到中等HER2陽性乳腺癌患者不符合曲妥珠單抗里，肽類藥物是一種肽為基礎的免疫療法旨在降低乳腺癌的複發率。","exchange":"NASDAQ","name":"Galena Biopharma","nameEN":"Galena Biopharma"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"GALE\",market:\"US\",,,undefined,":null}}